Recruiting

Omega Active

Sponsor:

Revive Active

Code:

NCT07753174

Conditions

Omega-3 Deficiency

DHA and EPA Blood Levels

Cardiovascular Health

Cognitive Health

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Interventions

Omega Active Supplement

Study Details

Brief summary:

This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing.

The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.

Conditions

Omega-3 Deficiency

DHA and EPA Blood Levels

Cardiovascular Health

Cognitive Health

Study ID

NCT07753174

Start date

Sep, 2026

Status verified date

Aug, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Be male or female.
  • Be aged 18-65.
  • Anyone in good general health.
  • Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
  • Must not have taken fish oil or plant-based omega oil supplements in the past eight weeks.
  • Willing to maintain their current diet, sleep schedule, and activity level for the duration of the study.
  • Resides in the United States.

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
  • Anyone on anticoagulants or antiplatelet therapy.
  • Anyone with a bleeding disorder.
  • Anyone with any allergies or sensitivities to any of the study product ingredients.
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
  • Anyone unwilling to follow the study protocol.
  • Anyone who does not consume any specific dietary ingredients for any reason.
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration.

Study Design

Enrollment

49 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Omega Active Supplement

Interventions

Omega Active Supplement

All participants receive one dose (two capsules) of the Omega Active omega-3 supplement daily for 12 weeks.

Primary outcome measure

  • Change in DHA levels in the blood [ Time Frame: Baseline and Week 12 ]
  • Change in EPA levels in the blood [ Time Frame: Baseline and Week 12 ]

Central Contacts and Locations

Central contacts

Patrick Renner

4242450284

Locations

Citruslabs

Recruiting

Las Vegas, Nevada, United States, 89101

More Information

Sponsor

Revive Active

Last update posted

Aug 7, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Revive Active on 2026-08-07.